1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Alfresa Holdings Corporation

Alfresa Holdings Corporation

2,406.50
JPY
+34.50
(+1.45%)
459.38BMarket Cap
Nov 09Next Earn
Alfresa Holdings Corporation
TSE:2784
(Tokyo Stock Exchange)

Recent

price

2,406.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
10,746.34
11,392.31
11,204.2
11,315.3
10,824.31
11,711.63
11,777.42
12,012.93
12,398.25
12,748.7
12,332.8
12,338.56
13,322.54
14,905.63
15,950.69
17,075.1
- -
Revenue per Share
32.42
32.24
97.48
115.5
102.48
158.99
142.57
164.25
195.91
190.26
115.75
153.57
127.42
154.13
147.54
229.64
- -
Basic EPS, GAAP
199.03
26.58
354.54
-218.69
89.08
107.25
95.69
162.49
155.94
62.61
-186.15
93.33
-61.17
370.49
-78.05
55.23
- -
Free Cash Flow per Basic Share
21.81
22.5
21.87
24
27.35
32.25
34
38
44.2
49
51
54.54
55.04
63.85
67.6
66.15
- -
Dividend per Share
1,135.38
1,152.27
1,281.91
1,379.04
1,576.06
1,691.63
1,810.66
2,006.52
2,083.02
2,237.88
2,313.65
2,330.34
2,411.88
2,566.5
2,650.26
2,791.99
- -
Book Value per Share
1,098.93
1,120.31
1,232.44
1,336.64
1,528.45
1,622.62
1,746.97
1,950.51
1,989.83
2,154.64
2,231.28
2,237.4
2,323.63
2,477.82
2,587.2
2,719.75
- -
Tangible Book Value per Share
203
205
213
221
224
220
217
217
213
212
212
210
202
192
186
182
181
Basic Weighted Avg Shares
2,183,356
2,333,465
2,387,435
2,504,574
2,421,105
2,576,360
2,551,919
2,602,925
2,640,529
2,698,555
2,610,521
2,585,643
2,696,069
2,858,500
2,961,051
3,104,064
- -
Sales/Revenue/Turnover
0.43
0.4
0.99
1.4
1.21
1.76
1.3
1.6
1.7
1.77
1.07
1.13
1.12
1.35
1.29
1.17
- -
Operating Margin (%)
9,340
9,308
10,819
10,011
9,374
10,850
11,017
10,564
10,756
11,777
11,868
12,824
13,302
13,514
14,923
15,048
- -
Depreciation Expense
6,587
6,604
20,771
25,566
22,922
34,975
30,893
35,589
41,724
40,273
24,501
32,182
25,786
29,558
27,389
41,746
- -
Net Income, GAAP
51.32
56.82
39.06
40.84
38.42
34.6
30.44
30.75
31.8
31.93
32.95
33.16
33.17
32.47
30.29
32.54
- -
Effective Tax Rate (%)
0.3
0.28
0.87
1.02
0.95
1.36
1.21
1.37
1.58
1.49
0.94
1.24
0.96
1.03
0.92
1.34
- -
Profit Margin (%)
89,293
91,982
115,917
123,155
132,369
129,623
148,296
166,313
176,873
197,433
208,551
213,658
208,795
214,244
199,535
220,840
- -
Working Capital
7,235
6,227
5,656
4,338
4,301
4,656
4,530
4,384
4,444
4,873
4,230
3,244
2,461
33,372
33,962
33,933
- -
LT Debt
236,768
244,014
283,954
305,435
354,120
368,728
393,547
435,932
442,080
474,897
489,957
471,832
488,334
479,858
482,246
507,900
- -
Total Equity
1.82
1.59
5.06
6.6
5.26
7.82
5.83
6.74
6.68
6.8
3.77
3.94
4.09
5.09
5.07
4.51
- -
Return on Invested Capital (%)
2.7
2.53
7.56
8.47
6.83
9.41
7.93
8.43
9.37
8.66
5.02
6.62
5.33
5.89
5.33
7.9
- -
Return on Capital (%)
2.92
2.8
7.94
8.68
6.97
9.73
8.14
8.61
9.53
8.81
5.09
6.7
5.37
6.11
5.7
8.44
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
1,687
- -
LT Borrowings
30,000
30,000
- -
LT Finance Leases
- -
3,933
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
182
182
175
Market Capitalization
384,608
459,383
381,349

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
1,147,871
1,159,314
- -
Cash, Cash Equivalents & STI
185,440
193,066
- -
Accounts Receivable, Net
680,953
682,707
- -
Inventories
178,022
172,858
- -
Total Current Liabilities
948,758
938,474
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,687
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.34%
0.78%
5.32%
Free Cash Flow
-168.2%
-255.32%
-169.3%
Net Income, GAAP
4.93%
14.24%
52.42%
Sales/Revenue/Turnover
1.92%
3.55%
4.83%
Total Cash Common Dividend
5.58%
2.32%
-4.18%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2,961,051
2026
- -
- -
- -
- -
3,104,064
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
147.54
2026
- -
- -
- -
- -
229.64
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
67.6
2026
- -
- -
- -
- -
66.15
2027
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Alfresa Holdings Corporation Alfresa Holdings Corporation (2784.T), founded on September 29, 2003 and headquartered at 1-1-3 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, manages subsidiaries engaged in the wholesaling, manufacturing, marketing, import/export of pharmaceuticals, diagnostic reagents, medical devices and equipment; it operates primarily in Japan with international activities. The company conducts business across four main segments: ethical pharmaceuticals wholesaling, which supplies prescription drugs, diagnostic reagents, medical devices, equipment and materials to hospitals, clinics and dispensing pharmacies; self-medication products wholesaling, offering over-the-counter drugs, health foods and supplements to drug stores and pharmacies; manufacturing, producing active pharmaceutical ingredients, finished pharmaceuticals, diagnostic reagents and medical devices including contract manufacturing services; and medical-related services, encompassing dispensing pharmacies and other healthcare support operations. In recent developments, Alfresa Holdings entered a capital and business alliance with GEXVal Inc. in March 2025 to develop high-quality drugs for rare diseases and underserved medical conditions; formed a business alliance with Minaris Regenerative Medicine Co., Ltd. in March 2025 to advance cell therapies and regenerative medicine through complementary manufacturing, procurement and distribution capabilities; signed a strategic partnership with HekaBio K.K. in June 2025, including capital investment, to accelerate commercialization of innovative therapies in CNS, oncology and regenerative medicine via Alfresa's total supply chain services in Japan and Asia-Pacific. Further, in January 2025, Alfresa Corporation, a key subsidiary, agreed to a business and capital alliance with Medley, Inc. involving share exchange to enhance digital transformation solutions for pharmacies, hospitals and clinics including electronic medication records; TS Alfresa Corporation acquired shares in Miyanomedix Inc. in September 2025 to bolster medical devices trading; established a basic business cooperation with K Pharma, Inc. in November 2025 for iPS cell-derived regenerative medicine supply chain, including investment in new bonds with warrants; and in September 2025, reached a basic agreement with Ai Ken Pharma Asia Pacific Holdings Pte. Ltd. for joint business development in Southeast Asia, focusing on full-agency pharmaceutical operations and sales channels for Japanese firms.

Company News

Company News APIChatGPT

  • globenewswire.com

    Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight